6/6 What are your thoughts? IRs using #AI will replace those who don’t! Save time, get smarter, & become AI enhanced! Be sure to subscribe our newsletter: https://t.co/xvxop1PZ7C Follow us on LinkedIn: https://t.co/r90x5SiAjj #VIR #iRads @CVIR_Journal @cvirendo @cirsesociety

5/6 📌 Conclusion: This study demonstrates high 12-month primary patency (89.5%) and low complication rates using retrievable scaffold therapy with sirolimus-coated balloon angioplasty for infrapopliteal lesions. Read more here:

4/6 By 12 months: 📈 89.5% primary patency ✅ 68.2% improved Rutherford class 🦶 90% low/very low amputation risk (WIfI scores) ✨ No additional major amputations or target lesion revascularizations #VascularHealth #PatientOutcomes

3/6 Results at 6 months: 🔹 11.5% primary safety events (1 mortality, 1 major amputation, 1 target lesion revascularization) 🔹 Late lumen loss: 0.7±0.7 mm 🔹 Negligible acute vessel recoil (2.4 mm to 2.3 mm)

2/6 The DEEPER LIMUS study focused on patients with Rutherford class 3 to 5 infrapopliteal artery disease. Participants underwent vessel preparation with retrievable scaffold therapy followed by sirolimus-coated balloon angioplasty 💉 #InterventionalRadiology #VascularSurgery

1/6 🚨 89.5% primary patency achieved in retrievable scaffold therapy with sirolimus-coated balloon angioplasty for infrapopliteal lesions! 🩺🌟 Check out the latest findings from @CVIR_Journal in their DEEPER LIMUS study👇 #Infrapopliteal #Angioplasty #VascularHealth

5/5 What are your thoughts? Stay at the forefront with #AI-enhanced #IR! Follow us for the latest research updates: https://t.co/xvxop1PZ7C Follow us on LinkedIn: https://t.co/r90x5SiAjj #VIR #InterventionalRadiology #IRadPulse @cvirendo @cirsesociety

4/5 📌 Conclusion: In this small study, PBNA achieved 100% technical success with no reported complications, bile leakages, or re-occlusions during a median follow-up of 2.8 years. Full study: https://t.co/gAanGqF9Wy #BiliarySurgery #Transplantation #MedTwitter

3/5 Key Findings: - Technical success: 100% - PTBDs removed median of 65 days post-procedure - Median follow-up: 2.8 years - Outcomes: No bile leakages or re-occlusions observed - Complications: None reported #PatientOutcomes #Safety

2/5 Study Details: - Participants: 4 patients (mean age 56) - Background: Right posterior bile duct exclusion and bile leakage after liver/pancreatic surgery or liver transplant - Method: Fluoroscopy-guided PBNA followed by PTBD #Hepatology

1/5 🚨 100% technical success in performing percutaneous biliary neo-anastomosis (PBNA) with fluoroscopy guidance!👇 Check out this recent study from @CVIR_Journal exploring the safety and effectiveness of PBNA for challenging biliary conditions 🧵 #BiliaryIntervention

6/6 What are your thoughts? Stay up-to-date with the latest in #VIR research. Subscribe to our newsletter: https://t.co/xvxop1PZ7C Follow us on LinkedIn: https://t.co/r90x5SiAjj #TransplantSpecialists #InnovativeCare @cvirendo @cirsesociety

5/6 📌 Conclusion: In this study, TACE with doxorubicin-eluting microspheres showed low HCC recurrence post-transplant, with lesion characteristics dictating recurrence risks. Dive deeper into the study: https://t.co/25vjY94pZX #MedicalResearch #InterventionalRadiology

4/6 Prognostic Insights: 🔑 Number and total size of HCC lesions at diagnosis and explant: • Key risk factors for recurrence • Number of lesions (p = 0.0088) & largest tumor size (p = 0.0179) #CancerResearch #Hepatology #VascularHealth

3/6 Results: 📌 Post-transplant HCC recurrence: • Bridging: 1 patient (3%) • Downstaging: 4 patients (23.5%) 📌 Disease-free survival at 5 years: • Bridging: 86% • Downstaging: 65% (p < 0.05) #LiverDisease #Chemoembolization

2/6 Study Focus: 🔍 286 patients undergoing liver transplantation for cirrhosis and early HCC (2006-2021) 🔍 53 received neoadjuvant TACE with doxorubicin-eluting microspheres 🔍 Two groups: Bridging (n=36) and downstaging (n=17) #TransplantSurgery #Oncology

1/6 🚨 Only 3% post-transplant recurrence in liver transplants after bridging TACE with doxorubicin-eluting microspheres! Discover new insights from @CVIR_Journal on transplant outcomes for HCC patients using this neoadjuvant technique 🧵 #LiverTransplant #HCC #TACE

6/6 What are your thoughts? IRs using #AI will replace those who don’t! Save time, get smarter, & become AI enhanced! Be sure to subscribe to our newsletter: https://t.co/xvxop1PZ7C Follow us on LinkedIn: https://t.co/r90x5SiAjj #VIR #iRads @SIRspecialists @SIRRFS

5/6 📌 Conclusion: University of Miami's endeavor provides a valuable roadmap for institutions aiming to develop standalone IR departments, highlighting vital strategies and potential hurdles. 🔗 Full study: https://t.co/4X1joiRP2F #IRSuccess #HealthcareInnovation #MedTwitter

4/6 Strategic Initiatives: 🔹 Separation of IR from diagnostic radiology budgets 🔹 Promotion of interdisciplinary research 🔹 Development of outpatient IR clinics for direct patient engagement #Research #PatientCare #ClinicManagement